Targets › CAPN2
1 program from 1 company in 1 trial: 1 Phase 1; Neurology; next expected readout Feb 2027.
Calcium-regulated non-lysosomal thiol-protease which catalyzes limited proteolysis of substrates involved in cytoskeletal remodeling and signal transduction. Proteolytically cleaves MYOC at 'Arg-226'. Proteolytically cleaves CPEB3 following neuronal stimulation which abolishes CPEB3 translational repressor activity, leading to translation of CPEB3 target mRNAs (By similarity). (UniProt, P17655)
Open in Phaseline: the race on CAPN2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Amylyx Pharmaceuticals | AMX0114 Antisense oligonucleotide targeting calpain-2 mRNA | CAPN2 | Phase 1 | ALS | Feb 2027 |
ALS (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.